CoviVac vaccine efficacy tentatively estimated at over 80% - developer
ST. PETESBURG. June 2 (Interfax) - The efficacy of the CoviVac coronavirus vaccine developed by the Chumakov Center exceeds 80%, however, the final stage of clinical trials is still ongoing, the Chumakov Center said in a material presented at the stand of the Russian Ministry of Science and Higher Education at the St. Petersburg International Economic Forum on Wednesday.
"The vaccine efficacy exceeds 80%, and the final stage of trials is not over yet," the Center said.
The Chumakov Center told Interfax in May that the third phase of clinical trials of the CoviVac coronavirus vaccine was due to begin in June.